Models and estimation methods for clinical HIV-1 data
暂无分享,去创建一个
[1] J. Jacquez,et al. Numerical parameter identifiability and estimability: Integrating identifiability, estimability, and optimal sampling design , 1985 .
[2] Hulin Wu,et al. Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. , 2003, Mathematical biosciences.
[3] Dani Gamerman,et al. Markov Chain Monte Carlo: Stochastic Simulation for Bayesian Inference , 1997 .
[4] James E. Bennett,et al. The Bayesian modeling of covariates for population pharmacokinetic models , 1996 .
[5] Adrian F. M. Smith,et al. Sampling-Based Approaches to Calculating Marginal Densities , 1990 .
[6] W. Gilks. Markov Chain Monte Carlo , 2005 .
[7] L. Skovgaard. NONLINEAR MODELS FOR REPEATED MEASUREMENT DATA. , 1996 .
[8] D. Richman,et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. , 2000 .
[9] Lewis B. Sheiner,et al. A general conceptual model for non-steady state pharmacokinetic/Pharmacodynamic data , 2006, Journal of Pharmacokinetics and Biopharmaceutics.
[10] Sylvia Richardson,et al. Markov Chain Monte Carlo in Practice , 1997 .
[11] Douglas M. Bates,et al. Nonlinear Regression Analysis and Its Applications , 1988 .
[12] L. Tierney,et al. Accurate Approximations for Posterior Moments and Marginal Densities , 1986 .
[13] Alan S. Perelson,et al. Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.
[14] R. Siliciano,et al. Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI , 1997, Journal of virology.
[15] M A Nowak,et al. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. , 1997, Journal of theoretical biology.
[16] Lewis B. Sheiner,et al. Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.
[17] D Johnson,et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. , 1999, AIDS.
[18] Claudio Cobelli,et al. Identifiability of compartmental systems and related structural properties , 1979 .
[19] David Z. D'Argenio,et al. Uncertain pharmacokinetic/pharmacodynamic systems: Design, estimation and control , 1997 .
[20] M. Pérez-Elías,et al. Percentage of Adherence Correlates with the Risk of Protease Inhibitor (PI) Treatment Failure in HIV-Infected Patients , 1998, Antiviral therapy.
[21] H. Akaike. A new look at the statistical model identification , 1974 .
[22] B. Efron,et al. Compliance as an Explanatory Variable in Clinical Trials , 1991 .
[23] M A Nowak,et al. Human immunodeficiency virus drug therapy and virus load , 1997, Journal of virology.
[24] D. Katz,et al. Bayesian Approach to the Analysis of Nonlinear Models: Implementation and Evaluation , 1981 .
[25] R. Siliciano,et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.
[26] E. Hannan. Rational Transfer Function Approximation , 1987 .
[27] N M Ferguson,et al. Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[28] E A Emini,et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.
[29] J Wakefield,et al. An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation. , 1995, Statistics in medicine.
[30] J Urquhart,et al. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. , 1998, Statistics in medicine.
[31] N. Draper,et al. Applied Regression Analysis , 1966 .
[32] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[33] F. Hecht,et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population , 2000, AIDS.
[34] A. Gelman,et al. Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .
[35] J A Jacquez,et al. Parameter estimation: local identifiability of parameters. , 1990, The American journal of physiology.
[36] Alan E. Gelfand,et al. Bayesian statistics without tears: A sampling-resampling perspective , 1992 .
[37] L. Ploughman,et al. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. , 2001, The Journal of infectious diseases.
[38] Davide Verotta,et al. A Non-linear Mixed Effect Dynamic Model Incorporating Prior Exposure and Adherence to Treatment to Describe Long-term Therapy Outcome in HIV-patients , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[39] D. Bates,et al. Newton-Raphson and EM Algorithms for Linear Mixed-Effects Models for Repeated-Measures Data , 1988 .
[40] Davide Verotta,et al. Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials. , 2002, Mathematical biosciences.
[41] L B Sheiner,et al. Semiparametric models for antagonistic drug interactions. , 1994, Journal of applied physiology.
[42] Donald Geman,et al. Stochastic Relaxation, Gibbs Distributions, and the Bayesian Restoration of Images , 1984, IEEE Transactions on Pattern Analysis and Machine Intelligence.